Kinase Inhibitors Toxicity Clinical Trial
— PAKITOOfficial title:
Identification of PAthways of Kinase Inhibitors TOxicity Through Patient Databases
| NCT number | NCT03896139 |
| Other study ID # | CIC1421-1906 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 1, 2017 |
| Est. completion date | March 1, 2019 |
| Verified date | March 2019 |
| Source | Groupe Hospitalier Pitie-Salpetriere |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
The investigators are identifying clinical diagnoses and toxicities associated with kinase inhibitors prescription. This identification will be applied will be applied in an electronic-health-record (EHR) cohort including North American and European.
| Status | Completed |
| Enrollment | 4000 |
| Est. completion date | March 1, 2019 |
| Est. primary completion date | March 1, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - Patient treated with a kinase inhibitor - Patient identified in the VUMC EHR cohort or having a toxicity reported in the VigiBase Exclusion Criteria: |
| Country | Name | City | State |
|---|---|---|---|
| France | AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Groupe Hospitalier Pitie-Salpetriere | Vanderbilt University Medical Center |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Comparison of the incidence of kinase inhibitor (KIs) induced toxicities in health records and their associations with co-medications to identify new mechanisms of drug induced toxicity | Identification of a mechanism of a toxicity associated with a KI using comedications and comparing it to reported outcomes | population included in VUMC database and/or WHO's database resource up to march 2019 |